Tech Company Financing Transactions
Amicus Therapeutics Funding Round
On 11/5/2010, Amicus Therapeutics announced $31.3 million in investment from private investors.
Transaction Overview
Company Name
Announced On
11/5/2010
Transaction Type
Venture Equity
Amount
$31,284,583
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 Cedar Brook Dr.
Cranbury, NJ 08512
USA
Cranbury, NJ 08512
USA
Phone
Website
Email Address
Overview
Amicus Therapeutics (Nasdaq:FOLD) is a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases. The Company has a robust development pipeline of treatments for a range of human genetic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Crowley
Chief Medical Officer
Jay Barth
Chief Operating Officer
Bradley Campbell
Chief Scientific Officer
Hung Do
Vice President
Jeffrey Castelli
VP - Finance
Daphne Quimi
Browse more venture capital transactions:
Prev: 11/5/2010: Wrightspeed venture capital transaction
Next: 11/6/2010: Trooval.com venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs